Ocean Genomics, a Pittsburgh, PA-based technology and AI company that has developed computational platforms to assist biopharma companies, received an investment from Accenture (NYSE: ACN).
The amount of the investment, made via Accenture Ventures, was not disclosed
The investment will accelerate the AI-driven drug discovery and the development of personalized medicines.
Led by Carl Kingsford, Ocean Genomics creates software that provides modeling and an understanding of changes and variants in mRNA to enable an accurate prediction of a patient’s biological response to a drug.
Its Intelligent Transcriptome computing platforms extract extensive gene expression features and analyses from raw RNA-Seq files (TxomeAI®), and automatically integrate those features with clinical and other -omics to produce accurate, actionable models, and discover drug targets and biomarkers (DiscoverAI™). The vast database (DeepSea™) provides deeply characterized transcriptomes, curated metadata, and pre-trained AI models to add power to discovery and analyses.
Biopharma companies use the technology in in-silico drug discovery to develop treatments based on an individual’s personal biology.
FinSMEs
21/02/2023